URO TODAY: Stopping the enzyme process that allows a prostate tumour to produce androgens could be the key in halting a tumour’s growth, researchers in Texas say. READ MORE> Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.
Archive for the ‘Hormone-refactory’ Category
Researchers find way to stop prostate cancer tumours from growing
Posted in Hormone therapy, Hormone-refactory, tagged advanced prostate cancer, androgens, blocking tumour growth, cancer research, catheter, enzyme process, hormone therapy resistance, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate tumours, tumour growth, URO TODAY on July 24, 2010 | Leave a Comment »
Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer
Posted in Chemotherapy, Hormone therapy, Hormone-refactory, PROSTATE CANCER, Prostate drugs, PROSTATE RESEARCH, tagged abiraterone acetate, advanced prostate cancer, cancer research, castration, castration-resistant disease, catheter, Chemotherapy, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment debate, URO TODAY on May 29, 2010 | Leave a Comment »
URO TODAY: Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have not had chemotherapy. A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>
Promising drugs being developed to prevent eventual failure of hormone therapy for prostate cancer
Posted in Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged abiraterone acetate, adrenal gland, advanced prostate cancer, androgen receptor, cancer research, CYP17A inhibitor, early phase trials, Hormone therapy, MDV3100, new anti-androgen, over-expressed androgen receptor, phase three testing, prostablog, prostate, prostate blog, prostate cancer growth, prostate cancer treatments, prostate treatment, prostate treatment debate, steroid biosynthesis, URO TODAY on October 30, 2009 | Leave a Comment »
URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen
Experiment with chemo combination works for hormone refractory prostate cancer patients
Posted in Chemotherapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, Treatment news, tagged advanced prostate cancer, cancer research, Chemotherapy, docetaxel/zoledronic/prednisone, Gleason score, hormone-refractory, Indian researchers, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, significantly better survival, URO TODAY on October 29, 2009 | 1 Comment »
URO TODAY: A combination of docetaxel/zoledronic/prednisone in chemotherpay for hormone refractory prostate cancer patients is safe and effective, say Indian researchers.
Early treatment recommended for depression brought on by hormone therapy for prostate cancer
Posted in Depression, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged cancer research, cognitive loss, comparison of treatments, depression, Hormone therapy, hormone therapy side effects, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, URO TODAY on October 27, 2009 | Leave a Comment »
URO TODAY: Depression and cognitive loss are common in men on hormone therapy for prostate cancer and early treatment with anti-depressants is recommended, according to a paper presented at a conference in Turkey.
New prostate cancer drugs give hope of further life beyond chemotherapy
Posted in Hormone-refactory, New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged abiraterone, advanced prostate cancer, androgen biosynthesis, androgen-deprivation therapy, beyond chemotherapy, cancer research, castrate-resistant prostate cancer, Chemotherapy, Hormone therapy, MDV3100, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, URO TODAY on October 8, 2009 | Leave a Comment »
URO TODAY: Once, chemotherapy (then death) were the only options left for prostate cancer patients on whom hormone therapy stopped working: now new drugs give hope of extended life.
Trial begins on new antagonist drug that takes over after docetaxel-based chemotherapy
Posted in Chemotherapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged advanced prostate cancer, AFFIRM, cancer research, castration-resistant prostate cancer, docetaxel-based chemotherapy, drug MDV3100, MEDICAL NEWS TODAY, novel androgen receptor antagonist, phase 3 clinical trial, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate on September 25, 2009 | Leave a Comment »
MEDICAL NEWS TODAY: A phase 3 clinical trial of the investigational drug MDV3100 for advanced prostate cancer has just begun in the US.
Low – not high – levels of testosterone may be new culprit in prostate cancer
Posted in Diagnosis, Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, Testosterone treatment, Treatment debate, tagged advanced stage of presentation, androgen-deprivation therapy, cancer research, high Gleason score, high serum testosterone, Hormone therapy, increased risk of biochemical recurrence after surgery, low serum testosterone, new testosterone evidence, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, testosterone, testosterone levels, URO TODAY, worrisome cancer features on September 6, 2009 | Leave a Comment »
URO TODAY: High levels of testosterone have until recently been regarded as dangerous for prostate cancer patients, but new evidence is emerging that suggests something different.
The older you are with high-risk prostate cancer, the better the outlook
Posted in Age factors, Hormone therapy, Hormone-refactory, tagged advanced prostate cancer, age factor, androgen-deprivation therapy, cancer research, castrate-resistant disease, clinical trials, Hormone therapy, older prostate cancer patients, prognosis, prognostic variables, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate treatment, secondary treatments, URO TODAY, worse prognosis, younger prostate cancer patients on September 4, 2009 | Leave a Comment »
URO TODAY: Younger men with high-risk prostate cancer appear to have worse prognosis than older men with similar disease, according to a study of 4000 men receiving hormone treatment
Search
Visits to this site
-
COMMENTS
dota 2 beta key give… on ETHNIC issues Mark Fredericks on Numb penis after brachytherapy… David on MARY and JOHN’S sto… David on MARY and JOHN’S sto… Neil on PROSTATE INQUIRY Mark Duff on MARY and JOHN’S sto… Mark Duff on MARY and JOHN’S sto… Keith McLeod on MY CANCER STORY Jim Tucker on NZ Parliament releases prostat… John Baker on MY CANCER STORY David Haas on NZ Parliament releases prostat… Joshua on How does ‘encouraging… Julia Roberts on MY CANCER STORY John McHugh M.D. on Undetectable PSA! Yep, I… qdulc4793 on Experiment with chemo combinat… 
Prostablog RSS – click here- Balanced account of PSA debate in NZ Herald November 25, 2011
- NZ Parliament releases prostate cancer report July 27, 2011
- Undetectable PSA! Yep, I’ll take it, thanks April 5, 2011
PROSTABLOG pages
Stories posted so far
TOPICS
- AFTER EFFECTS (198)
- Biochemical recurrence (59)
- Bone loss (23)
- Bowel (3)
- Depression (5)
- Erectile function (58)
- Hot flashes (2)
- Incontinence (35)
- Non-ejaculation (1)
- Shorter penis (3)
- AWARENESS and MEDIA (140)
- Books (5)
- Facebook (1)
- Good news recovery stories (16)
- NZ Media coverage (9)
- Prostate blogs (32)
- Prostate claims (32)
- Prostate media coverage (27)
- Prostate myths (9)
- Prostate polls (2)
- Prostate stories (26)
- Translating medical terms (2)
- Wives' stories (6)
- ETHNICITY (16)
- Maori mortality (7)
- FUND RAISING (76)
- Blue September (23)
- Movember (3)
- Rowing 4 Prostate (31)
- FUTURE PROSPECTS (9)
- METASTASIS (12)
- Bone cancer (9)
- NZ Prostate Cancer Foundation (9)
- OFFICIAL BODIES (56)
- PREVENTION/ALTERNATIVE REMEDIES (87)
- Acupuncture (1)
- Aspirin (1)
- Dietary intervention (41)
- Magnolia (1)
- Natural remedies (42)
- Omega 3 fatty acids (4)
- Pomegranate (3)
- Soy (7)
- Tomato powder (1)
- Vitamin A (1)
- Vitamin B (2)
- Vitamin D (6)
- Vitamin E (2)
- PROSTATE CANCER (1278)
- Coming out (7)
- PC general (2)
- Young patients (3)
- PROSTATE RESEARCH (827)
- PROSTATE RISKS (188)
- Age factors (13)
- Agent orange risk (2)
- Alcohol (3)
- Avoidance (30)
- Bone density (1)
- Calcium (3)
- DNA damage (6)
- Folic acid (11)
- High-fat diet (1)
- Insecticides (3)
- Metabolic syndrome (1)
- Obesity (9)
- Occupation (1)
- Red meat (4)
- Selenium (2)
- Smoking (2)
- Socio-economic status (4)
- Virus (3)
- Vitamin B12 (1)
- SCREENING and DIAGNOSIS (477)
- Biomarkers (17)
- Biopsy (38)
- Cancer aggression (7)
- Checkups (57)
- Diagnosis (112)
- Digital exams (6)
- Doctors' advice (35)
- Family history (4)
- Feedback (2)
- Gene fusion (2)
- Genetic testing (16)
- Gleason grade (17)
- Mis-diagnosis (3)
- MRI scans (4)
- New tests (30)
- Prostate advice (17)
- Prostate prognosis (33)
- PSA tests (218)
- Screening debate (234)
- T Scale (1)
- Urine test (10)
- Vaccines (3)
- SELECT COMMITTEE INQUIRY (25)
- SYMPTOMS (21)
- Enlarged prostate (7)
- Urination (16)
- TREATMENT (676)
- Brachytherapy (47)
- Castration (1)
- Catheters (13)
- Chemotherapy (28)
- Cryoablation (5)
- Cryotherapy (5)
- Exercise (2)
- Gene therapy (4)
- Hormone therapy (72)
- Hormone-refactory (22)
- Immunotherapy (11)
- Killer genes (1)
- Laser (1)
- Medical tourism (1)
- MRI (2)
- New prostate drugs (47)
- Over-treatment (3)
- Post-operative care (17)
- Prostate cancer recovery (17)
- Prostate drugs (22)
- Prostate massage (2)
- Proton therapy (9)
- Provenge (26)
- Radical prostatectomy (112)
- Radio surgery (5)
- Radiotherapy (83)
- Robotic surgery (8)
- Salvage therapy (7)
- Survival (25)
- Testosterone treatment (27)
- TomoTherapy (1)
- Trans-urethral re-section (2)
- Treatment cost (2)
- Treatment debate (195)
- Treatment followup (1)
- Treatment news (312)
- Ultrasound (8)
- Watchful waiting (27)
- Uncategorized (26)
- AFTER EFFECTS (198)
-
Jim's Flickr photos
More Photos
